AtonRa Partners’s Pacific Biosciences PACB Stock Holding History

AtonRa Partners’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$576K	Sell	58,722 -6,360	-10%	-$52K	1.15%	26
2023 Q3	$543K	Buy	65,082 +2,504	+4%	+$28.6K	1.14%	22
2023 Q2	$832K	Sell	62,578 -13,853	-18%	-$168K	1.29%	20
2023 Q1	$885K	Sell	76,431 -10,748	-12%	-$107K	1.29%	14
2022 Q4	$713K	Sell	87,179 -42,862	-33%	-$369K	0.91%	45
2022 Q3	$755K	Sell	130,041 -13,903	-10%	-$79.8K	0.74%	60
2022 Q2	$636K	Buy	143,944 +84,740	+143%	+$515K	0.58%	78
2022 Q1	$539K	Sell	59,204 -9,891	-14%	-$114K	0.29%	105
2021 Q4	$1.41M	Sell	69,095 -25,205	-27%	-$608K	0.49%	72
2021 Q3	$2.41M	Buy	94,300 +36,576	+63%	+$1.08M	0.81%	54
2021 Q2	$2.02M	Buy	57,724 +30,943	+116%	+$900K	0.74%	62
2021 Q1	$892K	Buy	+26,781	New	+$937K	0.4%	97

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AtonRa Partners's PACB Position: Q4 2023 in Review

AtonRa Partners reduced its Pacific Biosciences (PACB) stake by 9.8% in Q4 2023, selling an estimated $52K and leaving 58,722 shares worth $576K. The position accounts for 1.15% of the portfolio, ranked #26.

AtonRa Partners first reported a position in PACB in Q1 2021 and has held it in 12 quarters since. The position peaked at $2.41M in Q3 2021. 274 funds tracked by Wall St. Rank hold PACB as of Q4 2023.

AtonRa Partners held 58,722 shares of Pacific Biosciences worth $576K as of Q4 2023.
AtonRa Partners sold 6,360 Pacific Biosciences shares in Q4 2023, an estimated $52K.
Pacific Biosciences made up 1.15% of AtonRa Partners's portfolio in Q4 2023, its #26 holding.
AtonRa Partners first reported a position in Pacific Biosciences in Q1 2021 and has held it in 12 quarters since.
AtonRa Partners's Pacific Biosciences position peaked at $2.41M in Q3 2021.
274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.